The Full Story Is Available to STAT+ Subscribers

Radiopharmaceuticals, a promising new field of cancer drug development that aims to deliver targeted radiation directly to tumors, are facing safety concerns as more therapies enter clinical trials. While designed to be more precise than traditional whole-body radiation, the isotopes used in these drugs can inadvertently damage patients' kidneys, liver, or bone marrow as they travel to their targets. The field has attracted significant attention from the drug industry, but developers are discovering that the reality is not as clear-cut as initially hoped.

The full story is available to STAT+ subscribers. (STAT News) — This article is based on a source that is partially behind a paywall; details beyond this summary were not accessible.